Skip to content

Why single-cell technologies are vital for Endometriosis research webinar

Why single-cell technologies are vital for Endometriosis research


Learn why single-cell technologies are vital for Endometriosis research by watching our webinar

Endometriosis is a debilitating disease that affects 10% of women and girls of reproductive age. There is no cure, no certain cause and no non-invasive method of diagnosing the disease, leading to a reduced quality of life for the patients and a significant socio-economic burden. Join us on our webinar on why single-cell technologies are vital for endometriosis research.

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of this disease requires a novel research approach by single-cell analysis. Therefore, Prof. Dr. med. Müller started collaborating with Scailyte AG, the specialist in single-cell analysis. In a joint project, they strive to develop a non-invasive diagnosis method, and potentially a prognostic method to reduce the suffering of endometriosis patients. Prof. Mueller is a renowned gynaecologist and gynaecological oncologist, and managing director of the Women’s Health Clinic at the University Hospital of Bern (Inselspital). He is the founding member and current president of the working group for Endoscopic Gynecology.

Join this webinar with Prof. Mueller, in cooperation with Scailyte, to learn more about “Why single-cell technologies are vital for Endometriosis research.”

Watch the webinar here: https://youtu.be/XPmhGRy-1AY

 

 

About Scailyte

Scailyte AG is a data-driven biomarker discovery company, founded in Luzern, Switzerland in 2017. The ETH Spin-off is using cutting edge technologies within the single-cell space and a proprietary biomarker discovery platform to develop clinical diagnostic applications in oncology and women’s health. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018. www.scailyte.com
ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

Read more

Recent News

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Read more

Recent News

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t

Read more

Recent News

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics pow

Read more

Recent News

Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better

Read more

Recent News

VACANCY: Technical Lead / Product Owner for a clinical diagnostic software

Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

VACANCY: Data Scientist in Biomarker Discovery

Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

True precision medicine through single-cell science - Nature

ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m

Read more

Recent News

01 /04

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

Read more

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Read more

Recent News

02 /04

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t

Read more

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics pow

Read more

Recent News

03 /04

Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better

Read more

VACANCY: Technical Lead / Product Owner for a clinical diagnostic software

Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

04 /04

VACANCY: Data Scientist in Biomarker Discovery

Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

True precision medicine through single-cell science - Nature

ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m

Read more

Recent News